Treatment of refractory vasospastic angina complicated by acute pulmonary oedema with levosimendan: a case report

Abstract Background Vasospastic angina (VA) is an important cause of chest pain and patients often have 3- to 6-month clusters of recurrent attacks, separated by relatively asymptomatic periods. During these episodes the resulting myocardial ischaemia can lead to clinical complications of different severity, including acute myocardial infarction, acute heart failure, and cardiogenic shock. The management of severe and recurrent VA attacks is challenging, and no specific recommendations exist in recent cardiologic guidelines on the pharmacological strategy (inotropic/vasopressor agents) to adopt for this acute clinical setting. Case summary We present a case of recurrent episodes of VA complicated by acute pulmonary oedema and cardiogenic shock despite maximal tolerated therapy (intravenous calcium antagonist and nitrates) that was successfully treated with levosimendan. Discussion Levosimendan rapidly reverted cardiogenic shock, acute pulmonary oedema, and mitral regurgitation caused by a refractory coronary spasm, contributing to persistent clinical stabilization. Further evidence and a longer follow-up are needed to support our observation on the efficacy of levosimendan in this specific clinical setting.

[1]  Marco Valgimigli,et al.  2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). , 2018, European heart journal.

[2]  A. Cohen-Solal,et al.  The role of levosimendan in acute heart failure complicating acute coronary syndrome: A review and expert consensus opinion Nieminen, , 2022 .

[3]  F. Crea,et al.  The Who, What, Why, When, How and Where of Vasospastic Angina. , 2016, Circulation journal : official journal of the Japanese Circulation Society.

[4]  F. Ozturk,et al.  Levosimendan accelerates recovery in patients with takotsubo cardiomyopathy. , 2016, Cardiology journal.

[5]  G. Hindricks,et al.  Temporary left ventricular stimulation in patients with refractory cardiogenic shock and asynchronous left ventricular contraction: a safety and feasibility study. , 2013, Heart rhythm.

[6]  D. Atar,et al.  ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation , 2013 .

[7]  K. Dickstein,et al.  Overview of emerging pharmacologic agents for acute heart failure syndromes , 2008, European journal of heart failure.

[8]  H. Yasue,et al.  Coronary artery spasm--clinical features, diagnosis, pathogenesis, and treatment. , 2008, Journal of cardiology.

[9]  G. Filippatos,et al.  Effects of levosimendan on coronary artery flow and cardiac performance in patients with advanced heart failure , 2007, European journal of heart failure.

[10]  I. Édes,et al.  The levosimendan metabolite OR‐1896 elicits vasodilation by activating the KATP and BKCa channels in rat isolated arterioles , 2006, British journal of pharmacology.

[11]  M. Wheeler,et al.  Episodic coronary artery vasospasm and hypertension develop in the absence of Sur2 K(ATP) channels. , 2002, The Journal of clinical investigation.